BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SUL-238 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of SUL-238\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07322887-1639@assetmemo.bio
DTSTAMP:20261121T010125Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:SUL-238: Phase 2 readout est. (NCT07322887)
DESCRIPTION:SUL-238\, phase 2\, Parkinson's Disease.\nStudy: A Phase 2 Stud
 y to Assess the Effects of SUL-238 on High Energy Phosphates With ³¹P-MR
 S in Patients With Early\, Untreated Parkinson's Disease\nEstimated primar
 y completion: 1 May 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/sul-238#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07322887
URL:https://assetmemo.bio/drug/sul-238#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
